ClinicalTrials.gg
RecruitingNCT07090161Updated Feb 27, 2026

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

A Phase 2 interventional study of iloperidone and Placebo in Hypertension and Uncontrolled Hypertension, sponsored by Vanda Pharmaceuticals. Recruiting at 28 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Planned enrollment
569th of 1,779
240 · median 100
Started
2025
with 98 others
Phase 2
170 of 2,031
21 open now
Primary completion
2026-10
later than 70 of 367 live
Registered
1,908th of 2,031
by date

Among the 2,031 studies in Hypertension with a site in United States, this one is the 569th largest by planned enrollment of the 1,779 interventional ones that give a count, is one of 99 that started in 2025, is one of 170 in phase 2, reaches primary completion later than 70 of the 367 other live ones, and was the 1,908th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

267 more — sign in →

All 272 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,031 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

03

Conditions studied

  • Hypertension
  • Uncontrolled Hypertension

Browse trials for

Keywords

  • iloperidone
  • hypertension
  • uncontrolled hypertension
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SiSBP >/= 130 mmHg despite >8 weeks treatment w/ 1 or more antihypertensive therapies

Exclusion criteria

Exclusion Criteria:

  • Confirmed Grade 3/severe hypertension (SiSBP >/= 180 mmHg, SiDBP >/= 120 mmHg), unstable cardiac disease, renal insufficiency
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Experimental/Iloperidone

    Drug: iloperidone

  • Placebo comparator
    Placebo Comparator

    Drug: Placebo

Interventions

  • iloperidone

    Also known as: Fanapt

  • DrugPlacebo

    placebo comparator

06

What researchers measure

Primary outcomes

  1. Change from baseline to treatment week 4 in SiSBP

    Time frame: screening to treatment week 4

07

Study locations

18 of 28 sites recruiting
  • Vanda Investigative Site
    Phoenix, Arizona 85053, United States
    Not yet recruiting
  • Vanda Investigative Site
    Tempe, Arizona 85281, United States
    Recruiting
  • Vanda Investigative Site
    Tucson, Arizona 85715, United States
    Not yet recruiting
  • Vanda Investigative Site
    Chula Vista, California 91910, United States
    Recruiting
  • Vanda Investigative Site
    Dublin, California 94568, United States
    Recruiting
  • Vanda Investigative Site
    Valencia, California 91355, United States
    Not yet recruiting
  • Vanda Investigative Site
    Walnut Creek, California 94596, United States
    Recruiting
  • Vanda Investigative Site
    Doral, Florida 33172, United States
    Not yet recruiting
  • Vanda Investigative Site
    Fort Myers, Florida 33912, United States
    Recruiting
  • Vanda Investigative Site
    Columbus, Georgia 31904, United States
    Recruiting
  • Vanda Investigative Site
    Oak Brook, Illinois 60523, United States
    Recruiting
  • Vanda Investigative Site
    Tinley Park, Illinois 60477, United States
    Recruiting
  • Vanda Investigative Site
    El Dorado, Kansas 67042, United States
    Recruiting
  • Vanda Investigative Site
    Wichita, Kansas 67226, United States
    Recruiting
  • Vanda Investigative Site
    Lexington, Kentucky 40509, United States
    Recruiting
  • Vanda Investigative Site
    Hazelwood, Missouri 63042, United States
    Recruiting
  • Vanda Investigative Site
    Las Vegas, Nevada 89119, United States
    Not yet recruiting
  • Vanda Investigative Site
    Mount Kisco, New York 10549, United States
    Not yet recruiting
  • Vanda Investigative Site
    Rochester, New York 14609, United States
    Not yet recruiting
  • Vanda Investigative Site
    Kinston, North Carolina 28501, United States
    Recruiting
  • Vanda Investigative Site
    Cincinnati, Ohio 45212, United States
    Recruiting
  • Vanda Investigative Site
    Norman, Oklahoma 73069, United States
    Recruiting
  • Vanda Investigative Site
    Oklahoma City, Oklahoma 73112, United States
    Not yet recruiting
  • Vanda Investigative Site
    Charleston, South Carolina 29414, United States
    Recruiting
  • Vanda Investigative Site
    Carrollton, Texas 75006, United States
    Not yet recruiting
  • Vanda Investigative Site
    Salt Lake City, Utah 84124, United States
    Not yet recruiting
  • Vanda Investigative Site
    Burke, Virginia 22015, United States
    Recruiting
  • Vanda Investigative Site
    Norfolk, Virginia 23502, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Oct 2026, 13 months after the start.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 13 months is close to that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Jul 29, 2025
StartActual
Sep 15, 2025
Primary completionEst.
Oct 2026
CompletionEst.
Nov 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07090161
Responsible party
Sponsor
First posted
Jul 29, 2025
Start date
Sep 15, 2025
Primary completion
Oct 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Feb 27, 2026

Study contacts

Vanda Pharmaceuticals, Inc.
Contact
clinicaltrials@vandapharma.com
202-734-3400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iloperidone

Start the discussion